Cargando…
Pharmacologic inhibition of STAT5 in acute myeloid leukemia
The transcription factor STAT5 is an essential downstream mediator of many tyrosine kinases (TKs), particularly in hematopoietic cancers. STAT5 is activated by FLT3-ITD, which is a constitutively active TK driving the pathogenesis of acute myeloid leukemia (AML). Since STAT5 is a critical mediator o...
Autores principales: | Wingelhofer, Bettina, Maurer, Barbara, Heyes, Elizabeth C., Cumaraswamy, Abbarna A., Berger-Becvar, Angelika, de Araujo, Elvin D., Orlova, Anna, Freund, Patricia, Ruge, Frank, Park, Jisung, Tin, Gary, Ahmar, Siawash, Lardeau, Charles-Hugues, Sadovnik, Irina, Bajusz, Dávid, Keserű, György Miklós, Grebien, Florian, Kubicek, Stefan, Valent, Peter, Gunning, Patrick T., Moriggl, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940656/ https://www.ncbi.nlm.nih.gov/pubmed/29472718 http://dx.doi.org/10.1038/s41375-017-0005-9 |
Ejemplares similares
-
Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas
por: Orlova, Anna, et al.
Publicado: (2017) -
Direct Targeting Options for STAT3 and STAT5 in Cancer
por: Orlova, Anna, et al.
Publicado: (2019) -
The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease
por: Kosack, Lindsay, et al.
Publicado: (2019) -
Structural Implications of STAT3 and STAT5 SH2 Domain Mutations
por: de Araujo, Elvin D., et al.
Publicado: (2019) -
Targeting STAT3 and STAT5 in Cancer
por: de Araujo, Elvin D., et al.
Publicado: (2020)